收费全文 | 92170篇 |
免费 | 7928篇 |
国内免费 | 1790篇 |
耳鼻咽喉 | 818篇 |
儿科学 | 2036篇 |
妇产科学 | 1199篇 |
基础医学 | 4079篇 |
口腔科学 | 4704篇 |
临床医学 | 8734篇 |
内科学 | 10788篇 |
皮肤病学 | 1727篇 |
神经病学 | 5374篇 |
特种医学 | 2598篇 |
外国民族医学 | 21篇 |
外科学 | 10915篇 |
综合类 | 15681篇 |
现状与发展 | 9篇 |
一般理论 | 5篇 |
预防医学 | 7240篇 |
眼科学 | 1597篇 |
药学 | 8953篇 |
171篇 | |
中国医学 | 9141篇 |
肿瘤学 | 6098篇 |
2024年 | 214篇 |
2023年 | 1587篇 |
2022年 | 2173篇 |
2021年 | 3826篇 |
2020年 | 4112篇 |
2019年 | 3242篇 |
2018年 | 3061篇 |
2017年 | 3357篇 |
2016年 | 3639篇 |
2015年 | 3335篇 |
2014年 | 6535篇 |
2013年 | 8662篇 |
2012年 | 6264篇 |
2011年 | 6617篇 |
2010年 | 5477篇 |
2009年 | 4761篇 |
2008年 | 4201篇 |
2007年 | 4382篇 |
2006年 | 3941篇 |
2005年 | 3336篇 |
2004年 | 2814篇 |
2003年 | 2443篇 |
2002年 | 2095篇 |
2001年 | 1687篇 |
2000年 | 1427篇 |
1999年 | 1151篇 |
1998年 | 929篇 |
1997年 | 860篇 |
1996年 | 719篇 |
1995年 | 616篇 |
1994年 | 557篇 |
1993年 | 477篇 |
1992年 | 392篇 |
1991年 | 347篇 |
1990年 | 261篇 |
1989年 | 270篇 |
1988年 | 241篇 |
1987年 | 223篇 |
1986年 | 200篇 |
1985年 | 254篇 |
1984年 | 203篇 |
1983年 | 136篇 |
1982年 | 181篇 |
1981年 | 143篇 |
1980年 | 130篇 |
1979年 | 116篇 |
1978年 | 66篇 |
1977年 | 61篇 |
1976年 | 48篇 |
1975年 | 28篇 |
Areas covered: The many tools developed to measure disease activity in RA, from composite scores and patient-reported outcomes, to laboratory markers and imaging are discussed, with a focus on their utility in guiding therapy and assessing response. The complex issues in measuring disease activity in RA, whether in clinical trials or normal clinical practice, and in the context of national guidelines and recommendations, available time, and resources are considered.
Expert commentary: The key to effective management of RA is the rapid suppression of inflammation, ideally to remission, with maintenance of such remission. The aim is to prevent disability and maximize quality of life. Central to this is the ability to determine disease activity (potentially open to suppression) as opposed to damage (irreversible). A variety of measures are currently available, allowing better assessment of response to treatment. In the future, the development of predictive biomarkers allowing targeting of drugs may revolutionize this field and render the tools of today redundant. 相似文献
Methods: A systematic literature search was performed to identify relevant randomized controlled trials (RCTs). Key outcomes of interest were clinical response (CD activity index [CDAI] reduction of 100 points; CDAI-100) and remission (CDAI score under 150 points; CDAI < 150). A treatment sequence Bayesian NMA was conducted to account for the re-randomization of patients based on different clinical definitions, the lack of similarity of the common comparator for each trial and the full treatment pathway from the induction phase onwards.
Results: Thirteen RCTs were identified. Ustekinumab 90?mg q8w was associated with statistically significant improvement in clinical response relative to placebo and vedolizumab 300?mg. For clinical remission, ustekinumab 90?mg q8w was associated with statistically significant improvement relative to placebo and vedolizumab 300?mg q8w. Findings from sub-population analyses had similar results but were not statistically significant.
Conclusions: The NMA suggest that ustekinumab is associated with the highest likelihood of reaching response or remission at 1?year compared with placebo, adalimumab and vedolizumab. Results should be interpreted with caution because this is a novel methodology; however, the treatment sequence analysis may be the most methodologically sound analysis to derive estimates of comparative efficacy in CD in the absence of head-to-head evidence. 相似文献